Share Twitter LinkedIn Facebook Email Jeanny B. Aragon-Ching, MD, FACP, explains reliable molecular markers that can help identify high-risk muscle-invasive bladder cancer patients who should receive neoadjuvant therapy.
FDA Approves New Bladder Cancer Therapy: A Look at Anktiva Nogapendekin Alfa Inbakicept-pmln Bladder 4 Mins Read
